The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Strategies to optimize the outcomes of earlier-line patients treated with CAR T-cell therapy
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses possible approaches for improving early-line use of CAR T-cell therapy for multiple myeloma (MM) and highlights the current challenges with efficacy and treatment persistence, which should be addressed. Dr Costa also mentions some promising preclinical developments, such as administering cereblon E3 ligase modulators (CELMoDs) as maintenance or alongside a CAR-T product to improve CAR T-cell activation and persistence. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
